Ashpublications.org

Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome | Blood | American Society of Hematology
Ashpublications.org 91d 1 tweets
Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis | Blood Advances | American Society of Hematology
Ashpublications.org 92d 2 tweets
Abstract. Guidelines suggest thromboprophylaxis for ambulatory cancer patients starting chemotherapy with an intermediate to high risk of venous thromboembolis
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children | Blood Advances | American Society of Hematology
Ashpublications.org 92d 1 tweets
Key Points. Cytokine profiling can distinguish cytokine release syndrome after chimeric antigen receptor T-cell (CAR-T) therapy from sepsis.Cytokine profiling
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase | Blood Advances | American Society of Hematology
Ashpublications.org 92d 2 tweets
Key Points. The overall response rate for advanced phase MPN with decitabine/ruxolitinib therapy was 44% with a median OS of 9.5 months.This combination therap
Risk factors in MM: is it time for a revision? | Blood | American Society of Hematology
Ashpublications.org 93d 2 tweets
Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis | Blood | American Society of Hematology
Ashpublications.org 93d 1 tweets
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response | Blood Advances | American Society of Hematology
Ashpublications.org 93d 1 tweets
Key Points. CB-derived adoptive cell therapy is a feasible and efficacious therapeutic approach for patients with refractory AML.Treatment response depends on
Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia | Blood | American Society of Hematology
Ashpublications.org 93d 1 tweets
Neighborhood-Poverty and Pediatric Allogeneic Hematopoietic Cell Transplantation Outcomes: A CIBMTR Analysis | Blood | American Society of Hematology
Ashpublications.org 93d 1 tweets
Key Points. Neighborhood-poverty and public insurance are associated with inferior HCT outcomes in pediatric malignant disease.
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition | Blood | American Society of Hematology
Ashpublications.org 95d 1 tweets
Key Points. SARS-CoV-2 spike proteins bind heparan sulfate and activate the alternative complement pathway on cell surfaces.Factor D inhibitor (ACH-145951) blo
Morphologic remission status is limited compared to ΔN flow cytometry: a Children’s Oncology Group AAML0531 report | Blood Advances | American Society of Hematology
Ashpublications.org 95d 1 tweets
Key Points. Residual disease status by ΔN after first induction is the best predictor of OS in childhood AML.Lack of morphologic remission is a “false-positive
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia | Blood Advances | American Society of Hematology
Ashpublications.org 96d 1 tweets
Key Points. Multiple- and single-dose subcutaneous rozanolixizumab infusions were effective and well tolerated in patients with primary ITP.Single rozanolixizu
Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine | Blood Advances | American Society of Hematology
Ashpublications.org 96d 1 tweets
Key Points. Ponatinib produces a coronary microangiopathy that mimics myocardial infarction and can be detected rapidly by contrast echocardiography.N-acetylcy
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS | Blood Advances | American Society of Hematology
Ashpublications.org 96d 1 tweets
Key Points. Ibrutinib added to 10-day decitabine does not improve response or survival in newly diagnosed AML patients unsuitable for intensive chemotherapy.Mu
How I treat Adult T-cell leukemia/lymphoma | Blood | American Society of Hematology
Ashpublications.org 96d 1 tweets